Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors

Based on pre‐clinical and clinical activity in adult refractory tumors, and absence of significant neuro‐, nephro‐, or oto‐toxicity, we conducted a pediatric phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of satraplatin, an oral platinum analogue, in children and young adults with refractory solid tumors.

[1]  N. Bowden.  Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? , 2014, Cancer letters.

[2]  E. Giovannetti,et al.  Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. , 2014, Anticancer research.

[3]  Rui Gao,et al.  Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. , 2013, Clinical genitourinary cancer.

[4]  P. Steyger,et al.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Oh,et al.  Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  H. Lenz,et al.  ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis , 2011, Clinical Cancer Research.

[7]  F. Balis,et al.  The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates , 2011, Cancer Chemotherapy and Pharmacology.

[8]  William Berry,et al.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Tolcher,et al.  Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study , 2009, Clinical Cancer Research.

[10]  D. Frappaz,et al.  Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jimmy P. Xu,et al.  Preclinical antitumor activity of the oral platinum analog satraplatin , 2007, Cancer Chemotherapy and Pharmacology.

[12]  P. Perego,et al.  Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. , 2006, Biochemical pharmacology.

[13]  H. Choy.  Satraplatin: an orally available platinum analog for the treatment of cancer , 2006, Expert review of anticancer therapy.

[14]  M. McKeage,et al.  Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro , 2006, Cancer Chemotherapy and Pharmacology.

[15]  I. Judson,et al.  A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration , 2004, Cancer Chemotherapy and Pharmacology.

[16]  N. Saijo,et al.  Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. , 2000, Japanese journal of clinical oncology.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  E. Gehan,et al.  Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? , 2000, Journal of the National Cancer Institute.

[19]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[20]  H. Groen,et al.  Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Zucchetti,et al.  Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. Mushiroda,et al.  Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. , 1998, British Journal of Cancer.

[23]  P. Beale,et al.  Phase I study of oral JM216 given twice daily , 1998, Cancer Chemotherapy and Pharmacology.

[24]  I. Judson,et al.  Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Kèlland,et al.  Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. , 1996, Anticancer research.

[26]  C. O'Neill,et al.  Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. , 1994, British Journal of Cancer.

[27]  L. Kèlland,et al.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. , 1993, British Journal of Cancer.

[28]  L. Kèlland,et al.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.

[29]  L. Kèlland,et al.  Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. , 1992, Cancer research.

[30]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .